Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Liabilities (2017 - 2025)

Seres Therapeutics' Other Non-Current Liabilities history spans 9 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 12.96% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, up 12.96%, while the annual FY2024 figure was $1.8 million, 12.9% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $2.0 million at Seres Therapeutics, up from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $11.5 million in Q4 2021 and bottomed at $777000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $1.7 million (2024), against an average of $2.6 million.
  • The largest annual shift saw Other Non-Current Liabilities skyrocketed 1046.06% in 2021 before it tumbled 88.28% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $11.5 million in 2021, then crashed by 87.46% to $1.4 million in 2022, then rose by 12.9% to $1.6 million in 2023, then grew by 12.9% to $1.8 million in 2024, then rose by 9.58% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Other Non-Current Liabilities are $2.0 million (Q3 2025), $2.0 million (Q2 2025), and $1.9 million (Q1 2025).